Tagged with

US Generics & Biosimilars: Five Takeaways from Access! 2021
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual…

Dimitri Livadas – President & General Manager, Lilly…
Lilly Saudi Arabia’s Dimitri Livadas shares some of the misconceptions he had before moving to the Kingdom a couple of years ago, highlights the…

Georg Schroeckenfuchs of Novartis: ‘Shooting for the Moon’ in…
33-year pharma industry veteran Georg Schroeckenfuchs currently heads up the vast Middle East & Africa (MEA) region for Swiss behemoth Novartis,…

HKEX’s Aim to Become World’s #1 Biotech Listing Hub &…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar…

Aducanumab Approval: Opening the Floodgates for a New Era of…
With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease…

Singapore: A Myriad of Biotech Financing Strategies
Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative…

Mohamed Nasser – General Manager, Amgen Middle East &…
Amgen’s Middle East and Africa General Manager Mohamed Nasser discusses the company’s approach to the region; the opportunities in the Saudi…

Michael Hübner – New Venture Lead, Johnson & Johnson…
Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide, forming collaborations between entrepreneurs and the…

Switzerland’s Upcoming Cost Containment Packages: Industry…
While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland…

Newly Independent CDMO Skyepharma Looks to Expansion
Fresh from a management buyout and the establishment of Skyepharma as an independent company, Managing Director David Lescuyer charts the fully…

Georg Schroeckenfuchs – President MEA and Head Gulf &…
Georg Schroeckenfuchs, Novartis’ president MEA and head of its Gulf and Saudi Country Group, explains how the company’s objectives are aligned…

Philipp Haas – Chairman of BOD & CEO, DEVA
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp…
We use cookies to ensure that we give you the best experience on our site. For more info click here